DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data
Decomposing ROE involves expressing net income divided by shareholders’ equity as the product of component ratios.
Two-Component Disaggregation of ROE
Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)
|
|
|
|
|
|
|
ROE |
= |
ROA |
× |
Financial Leverage |
Dec 31, 2023 |
20.59% |
= |
15.92% |
× |
1.29 |
Sep 30, 2023 |
21.01% |
= |
15.97% |
× |
1.32 |
Jun 30, 2023 |
21.75% |
= |
16.54% |
× |
1.32 |
Mar 31, 2023 |
22.59% |
= |
17.18% |
× |
1.31 |
Dec 31, 2022 |
23.88% |
= |
18.30% |
× |
1.30 |
Sep 30, 2022 |
25.12% |
= |
19.59% |
× |
1.28 |
Jun 30, 2022 |
26.77% |
= |
20.50% |
× |
1.31 |
Mar 31, 2022 |
22.47% |
= |
17.19% |
× |
1.31 |
Dec 31, 2021 |
23.19% |
= |
17.44% |
× |
1.33 |
Sep 30, 2021 |
22.83% |
= |
17.25% |
× |
1.32 |
Jun 30, 2021 |
21.66% |
= |
16.30% |
× |
1.33 |
Mar 31, 2021 |
30.76% |
= |
22.80% |
× |
1.35 |
Dec 31, 2020 |
31.22% |
= |
23.07% |
× |
1.35 |
Sep 30, 2020 |
33.08% |
= |
23.81% |
× |
1.39 |
Jun 30, 2020 |
27.67% |
= |
20.37% |
× |
1.36 |
Mar 31, 2020 |
23.38% |
= |
16.99% |
× |
1.38 |
Dec 31, 2019 |
19.34% |
= |
14.15% |
× |
1.37 |
Sep 30, 2019 |
— |
= |
— |
× |
1.43 |
Jun 30, 2019 |
— |
= |
— |
× |
1.39 |
Mar 31, 2019 |
— |
= |
— |
× |
1.39 |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in financial leverage ratio.
Three-Component Disaggregation of ROE
Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)
|
|
|
|
|
|
|
|
|
ROE |
= |
Net Profit Margin |
× |
Asset Turnover |
× |
Financial Leverage |
Dec 31, 2023 |
20.59% |
= |
36.68% |
× |
0.43 |
× |
1.29 |
Sep 30, 2023 |
21.01% |
= |
35.94% |
× |
0.44 |
× |
1.32 |
Jun 30, 2023 |
21.75% |
= |
35.40% |
× |
0.47 |
× |
1.32 |
Mar 31, 2023 |
22.59% |
= |
35.40% |
× |
0.49 |
× |
1.31 |
Dec 31, 2022 |
23.88% |
= |
37.20% |
× |
0.49 |
× |
1.30 |
Sep 30, 2022 |
25.12% |
= |
37.62% |
× |
0.52 |
× |
1.28 |
Jun 30, 2022 |
26.77% |
= |
38.26% |
× |
0.54 |
× |
1.31 |
Mar 31, 2022 |
22.47% |
= |
30.84% |
× |
0.56 |
× |
1.31 |
Dec 31, 2021 |
23.19% |
= |
30.92% |
× |
0.56 |
× |
1.33 |
Sep 30, 2021 |
22.83% |
= |
30.52% |
× |
0.57 |
× |
1.32 |
Jun 30, 2021 |
21.66% |
= |
29.80% |
× |
0.55 |
× |
1.33 |
Mar 31, 2021 |
30.76% |
= |
43.06% |
× |
0.53 |
× |
1.35 |
Dec 31, 2020 |
31.22% |
= |
43.70% |
× |
0.53 |
× |
1.35 |
Sep 30, 2020 |
33.08% |
= |
44.91% |
× |
0.53 |
× |
1.39 |
Jun 30, 2020 |
27.67% |
= |
38.51% |
× |
0.53 |
× |
1.36 |
Mar 31, 2020 |
23.38% |
= |
31.35% |
× |
0.54 |
× |
1.38 |
Dec 31, 2019 |
19.34% |
= |
28.27% |
× |
0.50 |
× |
1.37 |
Sep 30, 2019 |
— |
= |
— |
× |
— |
× |
1.43 |
Jun 30, 2019 |
— |
= |
— |
× |
— |
× |
1.39 |
Mar 31, 2019 |
— |
= |
— |
× |
— |
× |
1.39 |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.
Five-Component Disaggregation of ROE
Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)
|
|
|
|
|
|
|
|
|
|
|
|
|
ROE |
= |
Tax Burden |
× |
Interest Burden |
× |
EBIT Margin |
× |
Asset Turnover |
× |
Financial Leverage |
Dec 31, 2023 |
20.59% |
= |
0.83 |
× |
0.99 |
× |
44.83% |
× |
0.43 |
× |
1.29 |
Sep 30, 2023 |
21.01% |
= |
0.81 |
× |
0.99 |
× |
45.10% |
× |
0.44 |
× |
1.32 |
Jun 30, 2023 |
21.75% |
= |
0.78 |
× |
0.99 |
× |
45.81% |
× |
0.47 |
× |
1.32 |
Mar 31, 2023 |
22.59% |
= |
0.78 |
× |
0.99 |
× |
45.83% |
× |
0.49 |
× |
1.31 |
Dec 31, 2022 |
23.88% |
= |
0.78 |
× |
0.99 |
× |
48.01% |
× |
0.49 |
× |
1.30 |
Sep 30, 2022 |
25.12% |
= |
0.81 |
× |
0.99 |
× |
46.95% |
× |
0.52 |
× |
1.28 |
Jun 30, 2022 |
26.77% |
= |
0.81 |
× |
0.99 |
× |
47.81% |
× |
0.54 |
× |
1.31 |
Mar 31, 2022 |
22.47% |
= |
0.86 |
× |
0.98 |
× |
36.80% |
× |
0.56 |
× |
1.31 |
Dec 31, 2021 |
23.19% |
= |
0.86 |
× |
0.98 |
× |
36.86% |
× |
0.56 |
× |
1.33 |
Sep 30, 2021 |
22.83% |
= |
0.79 |
× |
0.98 |
× |
39.42% |
× |
0.57 |
× |
1.32 |
Jun 30, 2021 |
21.66% |
= |
0.83 |
× |
0.98 |
× |
36.99% |
× |
0.55 |
× |
1.33 |
Mar 31, 2021 |
30.76% |
= |
0.84 |
× |
0.98 |
× |
52.07% |
× |
0.53 |
× |
1.35 |
Dec 31, 2020 |
31.22% |
= |
0.87 |
× |
0.98 |
× |
51.16% |
× |
0.53 |
× |
1.35 |
Sep 30, 2020 |
33.08% |
= |
0.93 |
× |
0.98 |
× |
49.43% |
× |
0.53 |
× |
1.39 |
Jun 30, 2020 |
27.67% |
= |
0.93 |
× |
0.98 |
× |
42.33% |
× |
0.53 |
× |
1.36 |
Mar 31, 2020 |
23.38% |
= |
0.87 |
× |
0.97 |
× |
37.14% |
× |
0.54 |
× |
1.38 |
Dec 31, 2019 |
19.34% |
= |
0.84 |
× |
0.96 |
× |
34.91% |
× |
0.50 |
× |
1.37 |
Sep 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
1.43 |
Jun 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
1.39 |
Mar 31, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
× |
1.39 |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the decrease in return on equity ratio (ROE) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.
Two-Component Disaggregation of ROA
Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)
|
|
|
|
|
|
|
ROA |
= |
Net Profit Margin |
× |
Asset Turnover |
Dec 31, 2023 |
15.92% |
= |
36.68% |
× |
0.43 |
Sep 30, 2023 |
15.97% |
= |
35.94% |
× |
0.44 |
Jun 30, 2023 |
16.54% |
= |
35.40% |
× |
0.47 |
Mar 31, 2023 |
17.18% |
= |
35.40% |
× |
0.49 |
Dec 31, 2022 |
18.30% |
= |
37.20% |
× |
0.49 |
Sep 30, 2022 |
19.59% |
= |
37.62% |
× |
0.52 |
Jun 30, 2022 |
20.50% |
= |
38.26% |
× |
0.54 |
Mar 31, 2022 |
17.19% |
= |
30.84% |
× |
0.56 |
Dec 31, 2021 |
17.44% |
= |
30.92% |
× |
0.56 |
Sep 30, 2021 |
17.25% |
= |
30.52% |
× |
0.57 |
Jun 30, 2021 |
16.30% |
= |
29.80% |
× |
0.55 |
Mar 31, 2021 |
22.80% |
= |
43.06% |
× |
0.53 |
Dec 31, 2020 |
23.07% |
= |
43.70% |
× |
0.53 |
Sep 30, 2020 |
23.81% |
= |
44.91% |
× |
0.53 |
Jun 30, 2020 |
20.37% |
= |
38.51% |
× |
0.53 |
Mar 31, 2020 |
16.99% |
= |
31.35% |
× |
0.54 |
Dec 31, 2019 |
14.15% |
= |
28.27% |
× |
0.50 |
Sep 30, 2019 |
— |
= |
— |
× |
— |
Jun 30, 2019 |
— |
= |
— |
× |
— |
Mar 31, 2019 |
— |
= |
— |
× |
— |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the decrease in return on assets ratio (ROA) over Q4 2023 is the decrease in asset turnover ratio.
Four-Component Disaggregation of ROA
Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)
|
|
|
|
|
|
|
|
|
|
|
ROA |
= |
Tax Burden |
× |
Interest Burden |
× |
EBIT Margin |
× |
Asset Turnover |
Dec 31, 2023 |
15.92% |
= |
0.83 |
× |
0.99 |
× |
44.83% |
× |
0.43 |
Sep 30, 2023 |
15.97% |
= |
0.81 |
× |
0.99 |
× |
45.10% |
× |
0.44 |
Jun 30, 2023 |
16.54% |
= |
0.78 |
× |
0.99 |
× |
45.81% |
× |
0.47 |
Mar 31, 2023 |
17.18% |
= |
0.78 |
× |
0.99 |
× |
45.83% |
× |
0.49 |
Dec 31, 2022 |
18.30% |
= |
0.78 |
× |
0.99 |
× |
48.01% |
× |
0.49 |
Sep 30, 2022 |
19.59% |
= |
0.81 |
× |
0.99 |
× |
46.95% |
× |
0.52 |
Jun 30, 2022 |
20.50% |
= |
0.81 |
× |
0.99 |
× |
47.81% |
× |
0.54 |
Mar 31, 2022 |
17.19% |
= |
0.86 |
× |
0.98 |
× |
36.80% |
× |
0.56 |
Dec 31, 2021 |
17.44% |
= |
0.86 |
× |
0.98 |
× |
36.86% |
× |
0.56 |
Sep 30, 2021 |
17.25% |
= |
0.79 |
× |
0.98 |
× |
39.42% |
× |
0.57 |
Jun 30, 2021 |
16.30% |
= |
0.83 |
× |
0.98 |
× |
36.99% |
× |
0.55 |
Mar 31, 2021 |
22.80% |
= |
0.84 |
× |
0.98 |
× |
52.07% |
× |
0.53 |
Dec 31, 2020 |
23.07% |
= |
0.87 |
× |
0.98 |
× |
51.16% |
× |
0.53 |
Sep 30, 2020 |
23.81% |
= |
0.93 |
× |
0.98 |
× |
49.43% |
× |
0.53 |
Jun 30, 2020 |
20.37% |
= |
0.93 |
× |
0.98 |
× |
42.33% |
× |
0.53 |
Mar 31, 2020 |
16.99% |
= |
0.87 |
× |
0.97 |
× |
37.14% |
× |
0.54 |
Dec 31, 2019 |
14.15% |
= |
0.84 |
× |
0.96 |
× |
34.91% |
× |
0.50 |
Sep 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
Jun 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
Mar 31, 2019 |
— |
= |
— |
× |
— |
× |
— |
× |
— |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the decrease in return on assets ratio (ROA) over Q4 2023 is the decrease in efficiency measured by asset turnover ratio.
Disaggregation of Net Profit Margin
Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)
|
|
|
|
|
|
|
|
|
Net Profit Margin |
= |
Tax Burden |
× |
Interest Burden |
× |
EBIT Margin |
Dec 31, 2023 |
36.68% |
= |
0.83 |
× |
0.99 |
× |
44.83% |
Sep 30, 2023 |
35.94% |
= |
0.81 |
× |
0.99 |
× |
45.10% |
Jun 30, 2023 |
35.40% |
= |
0.78 |
× |
0.99 |
× |
45.81% |
Mar 31, 2023 |
35.40% |
= |
0.78 |
× |
0.99 |
× |
45.83% |
Dec 31, 2022 |
37.20% |
= |
0.78 |
× |
0.99 |
× |
48.01% |
Sep 30, 2022 |
37.62% |
= |
0.81 |
× |
0.99 |
× |
46.95% |
Jun 30, 2022 |
38.26% |
= |
0.81 |
× |
0.99 |
× |
47.81% |
Mar 31, 2022 |
30.84% |
= |
0.86 |
× |
0.98 |
× |
36.80% |
Dec 31, 2021 |
30.92% |
= |
0.86 |
× |
0.98 |
× |
36.86% |
Sep 30, 2021 |
30.52% |
= |
0.79 |
× |
0.98 |
× |
39.42% |
Jun 30, 2021 |
29.80% |
= |
0.83 |
× |
0.98 |
× |
36.99% |
Mar 31, 2021 |
43.06% |
= |
0.84 |
× |
0.98 |
× |
52.07% |
Dec 31, 2020 |
43.70% |
= |
0.87 |
× |
0.98 |
× |
51.16% |
Sep 30, 2020 |
44.91% |
= |
0.93 |
× |
0.98 |
× |
49.43% |
Jun 30, 2020 |
38.51% |
= |
0.93 |
× |
0.98 |
× |
42.33% |
Mar 31, 2020 |
31.35% |
= |
0.87 |
× |
0.97 |
× |
37.14% |
Dec 31, 2019 |
28.27% |
= |
0.84 |
× |
0.96 |
× |
34.91% |
Sep 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
Jun 30, 2019 |
— |
= |
— |
× |
— |
× |
— |
Mar 31, 2019 |
— |
= |
— |
× |
— |
× |
— |
Based on:
10-K (reporting date: 2023-12-31),
10-Q (reporting date: 2023-09-30),
10-Q (reporting date: 2023-06-30),
10-Q (reporting date: 2023-03-31),
10-K (reporting date: 2022-12-31),
10-Q (reporting date: 2022-09-30),
10-Q (reporting date: 2022-06-30),
10-Q (reporting date: 2022-03-31),
10-K (reporting date: 2021-12-31),
10-Q (reporting date: 2021-09-30),
10-Q (reporting date: 2021-06-30),
10-Q (reporting date: 2021-03-31),
10-K (reporting date: 2020-12-31),
10-Q (reporting date: 2020-09-30),
10-Q (reporting date: 2020-06-30),
10-Q (reporting date: 2020-03-31),
10-K (reporting date: 2019-12-31),
10-Q (reporting date: 2019-09-30),
10-Q (reporting date: 2019-06-30),
10-Q (reporting date: 2019-03-31).
The primary reason for the increase in net profit margin ratio over Q4 2023 is the increase in effect of taxes measured by tax burden ratio.